This is based on an assumption that tuberous sclerosis (TS) is the most frequent syndromic presentation of cardiac tumors, and mTOR inhibitors are effective in treating CNS and kidney neoplasms of TS (Curatolo and Moavero 2012). This evidence concerns the gene MTOR and heart neoplasm.